Search from website
Search from website
Figure 1. Coomassie-stained SDS-PAGE analysis of monoclonal antibody to SARS-CoV-2 Spike RBD, clone 36A7. 4-12% gradient gel is used for analysis. Lane 1. Monoclonal antibody to SARS-CoV-2 Spike RBD, clone 36A7 (-DTT). Lane 2-3. Size marker. Lane 4. Monoclonal antibody to SARS-CoV-2 Spike RBD, clone 36A7 (+DTT).
Figure 2. HPLC analytical SEC for final product.
Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.
Figure 4. Octet RED96e analysis, antibody was loaded on sensor for capture of Spike S1 protein (blue line) and trimeric Spike protein (red line).
Catalogue #
R1-164-100
Name
Human IgG1-lambda antibody to SARS CoV-2 S1 RBD (clone 36A7)
Target
RBD protein SARS-CoV-2
Target Description
Recombinant SARS-CoV-2 RBD2 protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line
Clonality
Human monoclonal
Clone
36A7
Class
hIgG1
Reactivity
SARS-CoV-2 Spike RBD
Neutralizing properties: blocks S1 and ACE2 binding in Octet system; IC50 1250 ng/ml measured in live virus neutralization assay
Dissociation constant (KD)
6.27 x 10-12 M (measured against SARS-CoV-2 Trimeric Spike protein)
5.10 x 10-8 M (measured against SARS-CoV-2 Spike S1 protein)
Application
ELISA
ELISA:
0,04-0,08 ng/ml
Purification
Protein A affinity chromatography following desalting
Buffer
PBS pH 7.4
Shipping
Shipped at ambient temperature.
Storage
Store at +4 °C. Avoid multiple freeze-thaw cycles.
This product is for research use only
TECHNICAL ASSISTANCE
Please refer any technical questions to
technical.support@icosagen.com